Activity and safety of sunitinib in poor risk metastatic renal cell carcinoma patients
Purpose To assess the activity, safety and treatment patterns of sunitinib in patients with poor-risk metastatic renal cell carcinoma (mRCC). Materials and Methods We retrospectively reviewed the charts of poor risk patients treated with sunitinib from October...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sociedade Brasileira de Urologia
2014-12-01
|
| Series: | International Brazilian Journal of Urology |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382014000600835&lng=en&tlng=en |
| _version_ | 1818144977323032576 |
|---|---|
| author | Romualdo Barroso-Sousa Rodrigo R. Munhoz Milena P. Mak Leonardo G. Fonseca Angelo B. S. Fede Rudinei Diogo Marques Linck Clovis R. Coelho Camila M. V. Moniz Ciro E. Souza Carlos Dzik |
| author_facet | Romualdo Barroso-Sousa Rodrigo R. Munhoz Milena P. Mak Leonardo G. Fonseca Angelo B. S. Fede Rudinei Diogo Marques Linck Clovis R. Coelho Camila M. V. Moniz Ciro E. Souza Carlos Dzik |
| author_sort | Romualdo Barroso-Sousa |
| collection | DOAJ |
| description | Purpose To assess the activity, safety and treatment patterns of sunitinib in patients with poor-risk metastatic renal cell carcinoma (mRCC). Materials and Methods We retrospectively reviewed the charts of poor risk patients treated with sunitinib from October 2006 to July 2013 who met the eligibility criteria. The primary endpoint was overall survival (OS). Tumor radiological response was measured according to RECIST 1.1 and adverse events (AEs) were assessed through standard criteria. Results Median OS was 8.16 months (95% CI, 5.73-10.59). Of the 53 patients included in this analysis, 9 (17.0%) achieved partial response, 12 (22.6%) had stable disease. Median treatment duration was 3.30 months (95% CI: 1.96-4.63) and 26.4% of patients discontinued treatment due to toxicity. Grade 3 or higher AEs occurred in 39.6% of patients, the most common being fatigue (15.1%), neutropenia (9.5%), nausea, vomiting and diarrhea (7.5% each). Discussion Sunitinib may benefit some unselected poor-risk patients, although the rates of AEs and drug discontinuation suggest a need for careful patient monitoring. |
| first_indexed | 2024-12-11T11:56:08Z |
| format | Article |
| id | doaj.art-375918afa0b04176931af29148506301 |
| institution | Directory Open Access Journal |
| issn | 1677-6119 |
| language | English |
| last_indexed | 2024-12-11T11:56:08Z |
| publishDate | 2014-12-01 |
| publisher | Sociedade Brasileira de Urologia |
| record_format | Article |
| series | International Brazilian Journal of Urology |
| spelling | doaj.art-375918afa0b04176931af291485063012022-12-22T01:08:13ZengSociedade Brasileira de UrologiaInternational Brazilian Journal of Urology1677-61192014-12-0140683584110.1590/S1677-5538.IBJU.2014.06.16S1677-55382014000600835Activity and safety of sunitinib in poor risk metastatic renal cell carcinoma patientsRomualdo Barroso-SousaRodrigo R. MunhozMilena P. MakLeonardo G. FonsecaAngelo B. S. FedeRudinei Diogo Marques LinckClovis R. CoelhoCamila M. V. MonizCiro E. SouzaCarlos DzikPurpose To assess the activity, safety and treatment patterns of sunitinib in patients with poor-risk metastatic renal cell carcinoma (mRCC). Materials and Methods We retrospectively reviewed the charts of poor risk patients treated with sunitinib from October 2006 to July 2013 who met the eligibility criteria. The primary endpoint was overall survival (OS). Tumor radiological response was measured according to RECIST 1.1 and adverse events (AEs) were assessed through standard criteria. Results Median OS was 8.16 months (95% CI, 5.73-10.59). Of the 53 patients included in this analysis, 9 (17.0%) achieved partial response, 12 (22.6%) had stable disease. Median treatment duration was 3.30 months (95% CI: 1.96-4.63) and 26.4% of patients discontinued treatment due to toxicity. Grade 3 or higher AEs occurred in 39.6% of patients, the most common being fatigue (15.1%), neutropenia (9.5%), nausea, vomiting and diarrhea (7.5% each). Discussion Sunitinib may benefit some unselected poor-risk patients, although the rates of AEs and drug discontinuation suggest a need for careful patient monitoring.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382014000600835&lng=en&tlng=ensunitinib [Supplementary Concept]Carcinoma, Renal CellSafety |
| spellingShingle | Romualdo Barroso-Sousa Rodrigo R. Munhoz Milena P. Mak Leonardo G. Fonseca Angelo B. S. Fede Rudinei Diogo Marques Linck Clovis R. Coelho Camila M. V. Moniz Ciro E. Souza Carlos Dzik Activity and safety of sunitinib in poor risk metastatic renal cell carcinoma patients International Brazilian Journal of Urology sunitinib [Supplementary Concept] Carcinoma, Renal Cell Safety |
| title | Activity and safety of sunitinib in poor risk metastatic renal cell carcinoma patients |
| title_full | Activity and safety of sunitinib in poor risk metastatic renal cell carcinoma patients |
| title_fullStr | Activity and safety of sunitinib in poor risk metastatic renal cell carcinoma patients |
| title_full_unstemmed | Activity and safety of sunitinib in poor risk metastatic renal cell carcinoma patients |
| title_short | Activity and safety of sunitinib in poor risk metastatic renal cell carcinoma patients |
| title_sort | activity and safety of sunitinib in poor risk metastatic renal cell carcinoma patients |
| topic | sunitinib [Supplementary Concept] Carcinoma, Renal Cell Safety |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382014000600835&lng=en&tlng=en |
| work_keys_str_mv | AT romualdobarrososousa activityandsafetyofsunitinibinpoorriskmetastaticrenalcellcarcinomapatients AT rodrigormunhoz activityandsafetyofsunitinibinpoorriskmetastaticrenalcellcarcinomapatients AT milenapmak activityandsafetyofsunitinibinpoorriskmetastaticrenalcellcarcinomapatients AT leonardogfonseca activityandsafetyofsunitinibinpoorriskmetastaticrenalcellcarcinomapatients AT angelobsfede activityandsafetyofsunitinibinpoorriskmetastaticrenalcellcarcinomapatients AT rudineidiogomarqueslinck activityandsafetyofsunitinibinpoorriskmetastaticrenalcellcarcinomapatients AT clovisrcoelho activityandsafetyofsunitinibinpoorriskmetastaticrenalcellcarcinomapatients AT camilamvmoniz activityandsafetyofsunitinibinpoorriskmetastaticrenalcellcarcinomapatients AT ciroesouza activityandsafetyofsunitinibinpoorriskmetastaticrenalcellcarcinomapatients AT carlosdzik activityandsafetyofsunitinibinpoorriskmetastaticrenalcellcarcinomapatients |